|
1
|
Dy GW, Gore JL, Forouzanfar MH, Naghavi M
and Fitzmaurice C: Global burden of urologic cancers, 1990–2013.
Eur Urol. 71:437–446. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fenner A: Prostate cancer:
AS-contemplation, not intervention. Nat Rev Oncol. 12:5952015.
|
|
3
|
Tosoian JJ, Mamawala M, Epstein JI, Landis
P, Wolf S, Trock BJ and Carter HB: Intermediate and longer-term
outcomes from a prospective active-surveillance program for
favorable-risk prostate cancer. J Clin Oncol. 33:3379–3385. 2016.
View Article : Google Scholar
|
|
4
|
Attard G, Parker C, Eeles RA, Schröder F,
Tomlins SA, Tannock I, Drake CG and de Bono JS: Prostate cancer.
Lancet. 387:70–82. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heidenreich A, Abrahamsson PA, Artibani W,
Catto J, Montorsi F, Van Poppel H, Wirth M and Mottet N; European
Association of Urology, : Early detection of prostate cancer:
European Association of Urology recommendation. Eur Urol.
64:347–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Center MM, Jemal A, Lortet-Tieulent J,
Ward E, Ferlay J, Brawley O and Bray F: International variation in
prostate cancer incidence and mortality rates. Eur Urol.
61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kattan MW, Vickers AJ, Yu C, Bianco FJ,
Cronin AM, Eastham JA, Klein EA, Reuther AM, Edson Pontes J and
Scardino PT: Preoperative and postoperative nomograms incorporating
surgeon experience for clinically localized prostate cancer.
Cancer. 115:1005–1010. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mills AA: Throwing the cancer switch:
Reciprocal roles of polycomb and trithorax proteins. Nat Rev
Cancer. 10:669–682. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eryilmaz J, Pan P, Amaya MF,
Allali-Hassani A, Dong A, Adams-Cioaba MA, Mackenzie F, Vedadi M
and Min J: Structural studies of a four-MBT repeat protein MBTD1.
PLoS One. 4:e72742009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wismar J, Loffler T, Habtemichael N, Vef
O, Geissen M, Zirwes R, Altmeyer W, Sass H and Gateff E: The
Drosophila melanogaster tumor suppressor gene lethal(3)malignant
brain tumor encodes a proline-rich protein with a novel zinc
finger. Mech Dev. 53:141–154. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jacquet K, Fradet-Turcotte A, Avvakumov N,
Lambert JP, Roques C, Pandita RK, Paquet E, Herst P, Gingras AC,
Pandita TK, et al: The TIP60 complex regulates bivalent chromatin
recognition by 53BP1 through direct H4K20me binding and H2AK15
acetylation. Mol Cell. 62:409–421. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dewaele B, Przybyl J, Quattrone A, Finalet
Ferreiro J, Vanspauwen V, Geerdens E, Gianfelici V, Kalender Z,
Wozniak A, Moerman P, et al: Identification of a novel, recurrent
MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int
J Cancer. 134:1112–1122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Rooij JD, van den Heuvel-Eibrink MM,
Kollen WJ, Sonneveld E, Kaspers GJ, Beverloo HB, Fornerod M,
Pieters R and Zwaan CM: Recurrent translocation t(10;17)(p15;q21)
in minimally differentiated acute myeloid leukemia results in
ZMYND11/MBTD1 fusion. Genes Chromosomes Cancer. 55:237–241. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
De Braekeleer E, Auffret R, Douet-Guilbert
N, Basinko A, Le Bris MJ, Morel F and De Braekeleer M: Recurrent
translocation (10;17)(p15;q21) in acute poorly differentiated
myeloid leukemia likely results in ZMYND11-MBTD1 fusion. Leuk
Lymphoma. 55:1189–1190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Klymenko T, Papp B, Fischle W, Köcher T,
Schelder M, Fritsch C, Wild B, Wilm M and Müller J: A Polycomb
group protein complex with sequence-specific DNA-binding and
selective methyl-lysine-binding activities. Genes Dev.
20:1110–1122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Grimm C, de Ayala Alonso AG, Rybin V,
Steuerwald U, Ly-Hartig N, Fischle W, Müller J and Müller CW:
Structural and functional analyses of methyl-lysine binding by the
malignant brain tumour repeat protein Sex comb on midleg. EMBO Rep.
8:1031–1037. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen X, Xie W, Gu P, Cai Q, Wang B, Xie Y,
Dong W, He W, Zhong G, Lin T and Huang J: Upregulated WDR5 promotes
proliferation, self-renewal and chemoresistance in bladder cancer
via mediating H3K4 trimethylation. Sci Rep. 5:82932015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma X, Du T, Zhu D, Chen X, Lai Y, Wu W,
Wang Q, Lin C, Li Z, Liu L and Huang H: High levels of glioma tumor
suppressor candidate region gene 1 predicts a poor prognosis for
prostate cancer. Oncol Lett. 16:6749–6755. 2018.PubMed/NCBI
|
|
19
|
Cimino-Mathews A, Subhawong AP, Illei PB,
Sharma R, Halushka MK, Vang R, Fetting JH, Park BH and Argani P:
GATA3 expression in breast carcinoma: utility in triple-negative,
sarcomatoid, and metastatic carcinomas. Hum Pathol. 44:1341–1349.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bachmann IM, Halvorsen OJ, Collett K,
Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP and
Akslen LA: EZH2 expression is associated with high proliferation
rate and aggressive tumor subgroups in cutaneous melanoma and
cancers of the endometrium, prostate, and breast. J Clin Oncol.
24:268–273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gu P, Chen X, Xie R, Han J, Xie W, Wang B,
Dong W, Chen C, Yang M, Jiang J, et al: lncRNA HOXD-AS1 regulates
proliferation and chemo-resistance of castration-resistant prostate
cancer via recruiting WDR5. Mol Ther. 25:1959–1973. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen X, Gu P, Xie R, Han J, Liu H, Wang B,
Xie W, Xie W, Zhong G, Chen C, et al: Heterogeneous nuclear
ribonucleoprotein K is associated with poor prognosis and regulates
proliferation and apoptosis in bladder cancer. J Cell Mol Med.
21:1266–1279. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nady N, Krichevsky L, Zhong N, Duan S,
Tempel W, Amaya MF, Ravichandran M and Arrowsmith CH: Histone
recognition by human malignant brain tumor domains. J Mol Biol.
423:702–718. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang YQ, Wang PY, Wang YT, Yang GF, Zhang
A and Miao ZH: An update on Poly(ADP-ribose)polymerase-1 (PARP-1)
inhibitors: Opportunities and challenges in cancer therapy. J Med
Chem. 59:9575–9598. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kluzek K, Bialkowska A, Koczorowska A and
Zdzienicka MZ: Poly(ADP-ribose) polymerase (PARP) inhibitors in
BRCA1/2 cancer therapy. Postepy Hig Med Dosw (Online). 66:372–384.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao D, Herman JG and Guo M: The clinical
value of aberrant epigenetic changes of DNA damage repair genes in
human cancer. Oncotarget. 7:37331–37346. 2016.PubMed/NCBI
|
|
27
|
Kirmizis A, Bartley SM and Farnham PJ:
Identification of the polycomb group protein SU(Z)12 as a potential
molecular target for human cancer therapy. Mol Cancer Ther.
2:113–121. 2003.PubMed/NCBI
|
|
28
|
Ma X, Huang J, Tian Y, Chen Y, Yang Y,
Zhang X, Zhang F and Xue L: Myc suppresses tumor invasion and cell
migration by inhibiting JNK signaling. Oncogene. 36:3159–3167.
2017. View Article : Google Scholar : PubMed/NCBI
|
